ABIVAX Upcoming Events

2017 Financial Results to be announced on March 16, 2018

PARIS--(BUSINESS WIRE)--

Regulatory News:

ABIVAX (Paris: ABVX) (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.

• March 12-14, 2018: BIO-Europe Spring in AmsterdamProf. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105

• March 16, 2018: Full Year 2017 Financial Results
• March 19-20, 2018: BIO Asia International Conference in Tokyo
• April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco

About ABIVAX (www.abivax.com/en)

ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20180312006063/en/

ABIVAX
Finance
Didier Blondel
[email protected]
+33 1 53 83 08 41
or
Press Relations France
ALIZE RP
Caroline Carmagnol/Aurore Gangloff
[email protected]
+33 6 64 18 99 59
or
Investors Relations
LifeSci Advisors
Chris Maggos
[email protected]
+41 79 367 6254
or
Press Relations US
LifeSci Public Relations
Matt Middleman, M.D.
[email protected]
+1 646 627 8384
or
Investors and Press Relations Germany
MC Services AG
Anne Hennecke
[email protected]
+49 211 529 252 22

Source: ABIVAX

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In